HIGHLIGHTS OF PRESCRIBING INFORMATION …
2.2 Recommended Dosage for Treatment of Influenza . 2.3 Recommended Dosage for Prophylaxis of Influenza . 2.4 Dosage in Patients with Renal Impairment
Download HIGHLIGHTS OF PRESCRIBING INFORMATION …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Initial dose of 4 mg/kg over 90 minute IV infusion, …
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information …
HIGHLIGHTS OF PRESCRIBING INFORMATION The …
www.gene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for
Reference ID: 4212951 - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information …
Valcyte Master USPI - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VALCYTE ® safely and effectively. See full prescribing information …
HIGHLIGHTS OF PRESCRIBING INFORMATION - Genentech
www.gene.com2 FULL PRESCRIBING INFORMATION WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Herceptin administration can …
HIGHLIGHTS OF PRESCRIBING INFORMATION The dose for …
www.gene.comfull prescribing information warning: fatal infusion reactions, severe mucocutaneous reactions, hepatitis b virus reactivation and progressive
OCREVUS Prescribing Information - Genentech
www.gene.comHepatitis B Virus Screening Prior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening. OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBVtests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV
HIGHLIGHTS OF PRESCRIBING INFORMATION ACTEMRA …
www.gene.com162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response Patients at or above 100 kg weight 162 mg administered subcutaneously every week Giant Cell Arteritis (2.2) Recommended Adult Subcutaneous Dosage: The recommended dose of ACTEMRA for adult patients with GCA is 162 mg
XOLAIR Prescribing Information - Genentech
www.gene.comCorticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of XOLAIR therapy. (5.4) Eosinophilic Conditions: Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or Fever, Arthralgia, and Rash: Stop XOLAIR if patients develop signs and sickness. (5.6)
XOFLUZA Prescribing Information - Genentech
www.gene.comHypersensitivitysuch as anaphylaxis, angioedema,urticaria,and erythema multiforme: Initiate appropriate treatment if an allergic-like reaction occurs or is suspected. (5.1) Risk of bacterial infection:Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as,a complication of influenza.
Related documents
Guidelines for Outbreak Prevention, Control and …
www.albertahealthservices.caPopulation, Public and Indigenous Health . Guidelines for Outbreak Prevention, Control and Management in Supportive Living and Home Living Sites – 2018
Summary of Recommendations for Adult …
www.immunize.orgnant influenza vaccine (RIV) For people through age 18yrs, consult “Summary of Recommen-
Annex 4 - WHO
www.who.int153 Annex 4 Recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration
Recommended composition of influenza virus …
www.who.int20 February 2013 Page 1 of 21. Recommended composition of influenza virus vaccines for use in the 2013-2014 northern hemisphere influenza season …
THE REGIONAL PANDEMIC OUTBREAK RESPONSE …
www.vch.caThe first priority of a pandemic influenza response plan is to save lives and care for the ill, while minimizing social disruption in the community.
20111026 찾아가는제품화지원 ... - drug.mfds.go.kr
drug.mfds.go.kr국내개발신약현황 (2011년10월기준) 연번 제품명 회사명 종류 구분 허가일자 1 선플라주 sk케미칼 항암제(위암) 화학의약품 1999년7월15일
Anaesthesia and Psychiatric drugs (2) - FRCA
www.frca.co.ukSign up to receive ATOTW weekly - email [email protected]. MICROBIOLOGY FOR ANAESTHETISTS PART 1 - THE PHARMACOLOGY OF ANTIBACTERIAL AND ANTIVIRAL DRUGS ANAESTHESIA TUTORIAL OF THE WEEK 190